Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis.
The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.
Employment as a health promotion intervention for persons with multiple sclerosis.
Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis.
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.
Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity?
Presence of aberrant V<formula>_{H}</formula>6 domains in anti-interferon-γ autoantibodies in multiple sclerosis.
Phenytoin in acute optic neuritis: neuroprotective or not?
Should we feel free to use loco-regional anesthesia in multiple sclerosis?
No additional copies of HERV-Fc1 in the germ line of multiple sclerosis patients.
Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis; From the Safety Assessment of Biologic ThERapy (SABER) Study.
S1P1 Receptor Upregulation and Amelioration of Experimental Autoimmune Encephalomyelitis by an S1P1 Antagonist.
Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation.
Diagnostic uncertainty of tumefactive cystic demyelinating lesions.
A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.
Disability Identity Predicts Lower Anxiety and Depression in Multiple Sclerosis.
Bipolar disorder and multiple sclerosis: a case series.
Risk factors for increased multiple sclerosis susceptibility in the Iranian population.
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01)
Risk of fractures in patients with multiple sclerosis: A population-based cohort study.
Interleukin-6 control of early Theiler's Murine Encephalomyelitis Virus replication in macrophages occurs in conjunction with STAT1 activation and nitric oxide production.
Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients.
Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background.
Determinants of ligand binding and catalytic activity in the myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase.
Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders.
Pages
« first
‹ previous
…
329
330
331
332
333
334
335
336
337
…
next ›
last »